Applied Therapeutics & Whole Animal Imaging

CCR/KI长期以来一直使用小鼠研究癌症。在过去的十年里， 中心已经成功地产生了许多小鼠模型，这些小鼠模型产生的肿瘤与 人类疾病的贡献突变谱及其表型 特征包括进展到转移状态。现在有一个强大的驱动器，由两个Kl 科学家和工程师使用这些模型来测试潜在的治疗策略， 耐药机制。此外，这些模型是Kl工程师的关键资源， 用于测试肿瘤检测和监测装置的体内系统，药物递送系统，以及 化疗反应在目前的资助期间，Kl建立了一个新的设施，称为 应用治疗和整体动物成像（ATWAI）核心设施，作为一个集中的 资源，以支持和鼓励这些翻译的努力。ATWAI核心开发于两个 阶段。在理论上，核心小组建立了支持对全球气候变化的纵向研究所需的基础设施。 对治疗剂的反应和抗性，特别是整个动物成像模式。这 仪器使中心成员能够评估体内肿瘤动力学，包括跟踪肿瘤细胞的生长情况。 肿瘤的发展和转移，并跟踪它们对治疗的反应。接下来，在2008年， 招募了一位小鼠模型专家担任ATWAI核心的代理经理，目标是最大限度地减少 在建立和进行临床前试验中存在的无数障碍。ATWAI管理器提供 中心成员提供广泛和定制的咨询服务，研究者培训和实践 执行实验，以实现生物传感器，诊断， 疫苗、化学疗法、基因疗法或药物递送和靶向模式。因此，ATWAI 核心帮助中心成员带来小鼠模型，以承担潜在的疗法，并刺激 Kl工程师和科学家之间的合作，允许测试药物输送和肿瘤监测 系统在适当的体内模型中。新科赫公司计划扩建ATWAI核心 研究所建筑，包括新增人员和仪器。CCSG的支持对于 确保ATWAI核心的成功，这一目标完全符合NCI的前进愿望 翻译研究

The CCR/KI has a longstanding track record of using mice to study cancer. Over the last decade the Center has successfully generated numerous mouse models that develop tumors that closely resemble the human disease with regard to both the spectrum of contribufing mutations and their phenotypic characterisfics including progression to the metastafic state. There is now a strong drive by both Kl Scientists and Engineers to use these models to test potential therapeutic strategies and also explore mechanisms of drug resistance. Moreover, these models are a key resource for Kl Engineers, offering in vivo systems to test tumor detecfion and monitoring devices, drug delivery systems, and chemotherapeutic response. In the current funding period, the Kl has established a new facility, called the Applied Therapeutics & Whole Animal Imaging (ATWAI) Core Facility that exists as a centralized resource to support and encourage these translational efforts. The ATWAI Core developed in two phases. Inifially, the Core established the infrastructure necessary to support longitudinal studies of the response and resistance to therapeutic agents, particularly whole animal imaging modalities. This instrumentation has allowed Center members to assess tumor dynamics in vivo including tracking the development and metastasis of tumors and following their response to treatment. Next, in 2008, an expert in mouse models was recruited as Acting Manager of the ATWAI Core with the goal of minimizing the myriad hurdles that exist in setting up and conducting preclinical trials. The ATWAI manager provides Center members with a extensive and customized consultative services, investigator training, and handson execufion of experiments to enable on-site, high-quality in vivo trials for biosensors, diagnostics, vaccines, chemotherapies, gene therapy, or drug delivery and targefing modalifies. Thus, the ATWAI Core helps Center members to bring mouse models to bear on potenfial therapies, and spurs collaborafions between Kl engineers and scienfists to allow testing of drug delivery and tumor monitoring systems in appropriate in vivo models. An expansion of the ATWAI Core is planned for the new Koch Institute building, including addifional staff and instrumentation. Support from the CCSG is critical to ensure the success of this ATWAI Core, a goal that fits perfecfiy with the NCI's desire to advance translational research.